GlassScriptPhysician profile
Amish M Parikh
NPI 1902820830
$154,393.95
in general payments reported to CMS, 2019-2025
47 companies · $9,455 in 2025
The $9,455 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $16K · 2021: $26K · 2022: $26K · 2023: $24K · 2024: $9,628 · 2025: $9,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Travel and Lodging: $3,777 · Food and Beverage: $3,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,785.00 |
| Travel and Lodging | $3,777.20 |
| Food and Beverage | $3,733.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $100,766.48 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $24,893.52 | 2019-2025 | Jardiance |
| Biotronik INC. | $23,177.09 | 2019-2023 | Biomonitor |
| Novartis Pharmaceuticals Corporation | $852.57 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $614.69 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $500.99 | 2019-2025 | Baylis Medical Company Radiofrequency Puncture Generator, General - Therapies, Watchman Access System |
| Pfizer INC. | $362.19 | 2019-2025 | |
| Cvrx, INC. | $348.31 | 2022-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $302.39 | 2019-2023 | Xarelto |
| Amgen INC. | $275.66 | 2019-2025 | Repatha |
| Abiomed | $210.45 | 2023-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $184.54 | 2022-2024 | Onpattro |
| Novo Nordisk INC | $154.31 | 2021-2025 | Ozempic |
| Bolton Medical INC | $136.00 | 2025 | Thoraflex Hybrid, Gelweave |
| Esperion Therapeutics, INC. | $125.38 | 2021-2025 | Nexletol |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amish Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.